ESR1 and breast carcinoma: Previously, in 143 consecutive estrogen receptor-positive/HER-negative (ER+/HER2−) breast cancer patients, we found a significant association between patient outcome and selected PET parameters measured at baseline: tumor SUVmax, MTV, total lesion glycolysis, and entropy [32].